Immugenyx, a wholly-owned subsidiary of Hemogenyx Pharmaceuticals, has developed a new type of humanised mouse called Advanced peripheral blood Hematopoietic Chimera (ApbHC) to help develop treatments against unknown human-specific pathogens.
Initially developed as a research and development tool to investigate mature blood cell populations such as human T-cells, B-cells and antibody-producing plasma cells, ApbHC presents various advantages compared to other mouse models.
Hemogenyx established Immugenyx to develop and commercialise its advanced Hematopoietic Chimeras (AHC) or humanised mice.
The company has demonstrated that the new mouse model has the potential to be used for testing multi-specific antibodies, including its own bi-specific CDX antibody to remove acute myeloid leukaemia (AML) and the conditioning of patients for bone marrow transplantation.
Additionally, ApbHC may be used to develop and test new cell therapies involving immune cell reprogramming, such as CAR-T.
Hemogenyx Pharmaceuticals CEO Vladislav Sandler said: “The ApbHC has allowed us to rapidly obtain in vivo data on the efficacy of our CDX antibodies against AML.
“We are actively developing and expanding the potential use of the ApbHC for disease modelling, the development of new therapeutics, and biodefense applications.
“Our ApbHC has also generated significant interest from third parties who also see its potential for disease modelling and drug development.”
Furthermore, the ApbHC can potentially be used for the modelling of autoimmune diseases, such as Systemic Lupus Erythematosus (aka Lupus).
It could also be used as a tool for the development and/or isolation of human antibodies against unknown human-specific pathogens.